info@oncogenpharma.com.pk (021) 38899090

Targeted Therapies

Precision oncology through targeted therapies

At Oncogen Pharma, our Targeted Therapies portfolio is focused on advancing cancer treatment through precision-based medicines designed to act on specific molecular pathways involved in tumor growth and progression. By targeting cancer cells more selectively, these therapies aim to improve treatment outcomes while supporting a better quality of life for patients. Our focus is to support oncologists and healthcare institutions with trusted therapies that meet international quality standards while ensuring affordability for the communities we serve.

Flag Image
Abytiga (Abiraterone Acetate) — 500 mg, 250 mg
Abiraterone Acetate

Abytiga

500 mg 250 mg
Imatigliv (Imatinib) — 400 mg, 100 mg
Imatinib

Imatigliv

400 mg 100 mg
Jaklitinib (Ruxolitinib) — 15 mg, 5 mg
Ruxolitinib

Jaklitinib

15 mg 5 mg
Lemiryl (Lenalidomide) — 25 mg, 10 mg, 5 mg
Lenalidomide

Lemiryl

25 mg 10 mg 5 mg
Lenvagen (Lenvatinib) — 10 mg, 4 mg
Lenvatinib

Lenvagen

10 mg 4 mg
Nilosigna (Nilotinib) — 200 mg, 150 mg
Nilotinib

Nilosigna

200 mg 150 mg
Oncolib (Palbociclib) — 125 mg, 100 mg, 75 mg
Palbociclib

Oncolib

125 mg 100 mg 75 mg
Osivant (Osimertinib) — 80 mg
Osimertinib

Osivant

80 mg
Pazorene (Pazopanib) — 400 mg, 200 mg
Pazopanib

Pazorene

400 mg 200 mg

Note: Product information is intended for formal healthcare, distribution, and business inquiries. Medicines should be used only under the guidance of qualified healthcare professionals and applicable regulatory requirements.